二咖啡基酸:一种潜在的胺β聚合抑制剂
Yue Sun1,2, Xue Wang3, Xiaoyu Zhang4
1College of Chemical Engineering, Shenyang University of Chemical Technology, Shenyang, 110142, China.
Journal of natural medicines
|June 26, 2024
概括
传统中医药的化合物,特别是1,3-di-caffeoylquinic acid,通过抑制粉样β (Aβ) 聚合和保护细胞免受损伤,显示出对抗阿尔茨海默病 (AD) 的承诺.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,治疗选择有限.
- 传统中医 (TCM) 为新型AD治疗提供了一个潜在的来源.
- 粉样β (Aβ) (1-40) 聚合是阿尔茨海默病的一个关键病理标志.
研究的目的:
- 选TCM化合物以检测它们抑制Aβ (1-40) 聚合的能力.
- 为了确定特定的分子相互作用和作用机制.
- 评估已识别的化合物的治疗潜力和细胞效应.
主要方法:
- 提奥夫拉T光试验用于选Aβ (1-40) 聚合抑制剂.
- 核磁共振 (NMR) 光谱 (2D15N-H异核单量子连贯性) 用于分子相互作用分析.
- 分子对接模拟以预测结合模式.
- 细胞测试以评估毒性,线粒体膜潜力,亡和Aβ (1-40) 诱导的损伤.
主要成果:
- 八种TCM化合物抑制了Aβ (1-40) 聚合;1,3-二-咖啡酸显示出最强的结合亲和力 (KD = 26.7 nM).
- 1,3-di-caffeoylquinic酸通过与基和氨基酸残留物,特别是Met-35.5的相互作用来破坏Aβ (1-40) 聚合.
- 鉴定到的化合物,特别是1,3-二-咖啡烯基酸,具有低毒性,通过调节线粒体功能和减少亡,保护细胞.
结论:
- 1,3-di-caffeoylquinic酸是Aβ (1-40) 聚合的强有力的抑制剂,具有治疗阿尔茨海默病的治疗潜力.
- 这项研究阐明了TCM化合物干扰Aβ (1-40) 聚合的分子机制.
- 来自TCM的catechol化合物代表了开发新型阿尔茨海默病干预措施的有希望的途径.
相关概念视频
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


